LMR Partners’s Janux Therapeutics JANX Stock Holding History

LMR Partners’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-57,000	Closed	-$1.42M	–	1099
2021 Q2	$1.42M	Buy	+57,000	New	+$1.27M	0.02%	455

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LMR Partners's JANX Position: Q3 2021 in Review

LMR Partners sold out of Janux Therapeutics (JANX) in Q3 2021, closing a stake of 57,000 shares — an estimated $1.42M sold.

LMR Partners first reported a position in JANX in Q2 2021 and held it in 1 quarter. The position peaked at $1.42M in Q2 2021. 45 funds tracked by Wall St. Rank hold JANX as of Q3 2021.

LMR Partners reported no remaining Janux Therapeutics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 57,000 Janux Therapeutics shares in Q3 2021, an estimated $1.42M.
LMR Partners first reported a position in Janux Therapeutics in Q2 2021 and held it in 1 quarter.
LMR Partners's Janux Therapeutics position peaked at $1.42M in Q2 2021.
45 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.